Abstract
It has been long known that the immune system interacts with tumor cells (1-12) and scientists have long believed that tumors carry surface molecules, antigens, that are recognized by the immune system and can induce a protective immune response. Advances in molecular biology and immunology in the past two decades have provided concrete evidence for the presence of these antigens, which are called tumor-associated antigens (TAA) and also provided the tools for the potential development of immunologic approaches to target cells carrying these antigens.
Keywords
- Major Histocompatibility Complex
- Major Histocompatibility Complex Class
- Cancer Vaccine
- Major Histocompatibility Complex Molecule
- Specific Immune Response
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Uenishi T, Hirohashi K, Tanaka H, Ikebe T, Kinoshita H. Spontaneous regression of a large hepatocellular carcinoma with portal vein tumor thrombi: report of a case. Surg Today 2000; 30: 82–85.
Hachiya T, Koizumi T, Hayasaka M, et al. Spontaneous regression of primary mediastinal germ cell tumor. Jpn J Clin Oncol 1998; 28: 281–283.
Markowska J, Markowska A. Spontaneous tumor regression. Ginekol Pol 1998; 69: 39–44.
Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000; 6: 253–262.
Penn I. Overview of the problem of cancer in organ transplant recipients. Ann Transplant 1997; 2: 5–6.
Konety BR, Tewari A, Howard RI, et al. Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery. Urology 1998; 52: 428–432.
Flattery MP. Incidence and treatment of cancer in transplant recipients. J Transpl Coord 1998; 8:105–110; quiz 111–112.
Sheil AG. Cancer in immune-suppressed organ transplant recipients: aetiology and evolution. Transplant Proc 1998; 30: 2055–2057.
Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996; 2: 91.
Bourantas KL, Hatzimichael EC, Makis AC, et al. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. Eur J Haematol 2000; 64: 350–351.
Parkinson DR, Sznol M. High dose interleukin-2 in the therapy of metastatic renal cell carcinoma. Semin Oncol 1995; 22: 61–66.
Stadler WM, Vogelzang NJ. Low dose interleukin-2 in the treatment of metaststic renal call carcinoma. Semin Oncol 1995; 22: 67–73.
Coley W. Treatment of inoperable malignant tumors with toxins of erysipelas and the bacillus prodigious. Trans Am Surg Assn 1894; 12: 183–212.
Nauts H. Beneficial effects of immunotherapy (bacterial toxins) on sarcoma of the soft tissue, other than lymphosarcoma. End results in 186 determinate cases with microscopic confirmation of diagnosis-49 operable, 137 inoperable. Cancer Research Institute, New York 1975.
Coley W. Cancer of the testis; containing a report of 64 cases, with special reference to 12 cases of cancer of the undescended testis. Trans South Surg Gyn Assn 1914; 63: 35–70.
Coley W. Primary neoplasms of the lymphatic glands including Hodgkin’s disease. Ann Surg 1916; 63: 35–70.
Coley W, Hoguet J. Melanotic cancer; with a report of ninety cases. Trans Am Surg Assn 1916; 34: 319–383.
Coley W. Multiple myeloma. Ann Surg 1931; 93: 77–89.
Coley W. Endothelioma, or Ewing’s tumor. Am J Surg 1935; 27: 7–18.
Roitt BJ I, Male D. Immunology. Mosby International, London, 1998.
Prehn R and Main JM. Immunity to methycholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769–778.
Klein G, Sjogren HO, Klein E, Hellström KE. Demonstration of resistance against methycholanthrene-induced sarcomas in the primary autochthonous host. 1960; 20: 1561–1572.
Wilkinson KD. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome [in process citation]. Semin Cell Dev Biol 2000; 11: 141–148.
Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci USA 1992; 89: 8918–8922.
Brodsky FM, Lem L, Bresnahan PA. Antigen processing and presentation [see comments]. Tissue Antigens 1996; 47: 464–471.
Lurquin C, Van PA, et al. Structure of the gene of turn-transplantation antigen P9 IA: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989; 58: 293–303.
De Plaen E, Lurquin C, Van PA, et al. Immunogenic (turn-) variants of mouse tumor P815: cloning of the gene of turn-antigen P91A and identification of the turn-mutation. Proc Natl Acad Sci USA 1988; 85: 2274–2278.
Davis MM, Chien Y. Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes. Curr Opin Immunol 1993; 5: 45–49.
Hanau D, Saudrais C, Haegel-Kronenberger H, Bohbot A, De La Salle H, Salamero J. Fate of MHC class II molecules in human dendritic cells. Eur J Dermatol 1999; 9: 7–12.
Batalia MA, Collins EJ. Peptide binding by class I and class II MHC molecules. Biopolymers 1997; 43: 281–302.
Wubbolts R, Neefjes J. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors. Immunol Rev 1999; 172: 189–208.
Pareja E, Tobes R, Martin J, Nieto A. The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells. Tissue Antigens 1997; 50: 421–428.
Solheim JC. Class I MHC molecules: assembly and antigen presentation. Immunol Rev 1999; 172: 11–19.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432–436.
Ropke M, Hald J, Guldberg P, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996; 93: 14704–14707.
Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92: 11993–11997.
Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185: 833–841.
Peace DJ, Chen W, Nelson H, Cheever MA. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 1991; 146: 2059–2065.
Yanuck M, Carbone DP, Pendleton DC, et al. A mutant p53 or ras tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res 1993; 53: 3257–3261.
Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999; 22: 155–165.
Wolfel T, Hauer M, Schneider J, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281–1284.
Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182: 323–331.
Kawakami Y, Robbins PF, Rosenberg SA. Human melanoma antigens recognized by T lymphocytes. Keio J Med 1996; 45: 100–108.
Worley BS, van den Broeke LT, Goletz TJ, et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001; 61: 6868–6875.
Nevins JR. Cell cycle targets of the DNA tumor viruses. Curr Opin Genet Dev 1994; 4: 130–134.
Levine AJ. The origins of the small DNA tumor viruses. Adv Cancer Res 1994; 65: 141–168.
Arvin AM, Mallory S, Moffat JF. Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 1999; 3: 193–200.
Liljeqvist S, Stahl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73: 1–33.
Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999; 11: 50–57.
Rolph MS, Ramshaw IA. Recombinatn viruses as vaccines and immunological tools [see comments]. Curr Opin Immunol 1997; 9: 517–524.
Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic Tlymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996; 156: 2369–2375.
Romani N, Gruner S, Brand D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83–93.
Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–296.
Takahashi H, Nakagawa Y, Yokomuro K, et al. Induction of CD8+ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol 1993; 5: 849–857.
Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med 1996; 183: 283–287.
Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183: 1357–1365.
Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–58.
Mitsudomi T, Steinberg SM, Nau MM, et al. P53 or Ras gene mutations in non-small lung cancer cell line and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171–180.
Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutation in non small cell lung cancer are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999–5002.
Peace DJ, Smith JW, Chen W, et al. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 1994; 179: 473–479.
Peace DJ, Smith JW, Disis ML, Chen W, Cheever MA. Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein. J Immunother 1993; 14: 110–114.
Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutatnt ras oncogene peptides that activate CD4+ an CD8+ T cell responses. Eur J Immunol 1996; 26: 435–443.
Abrams SI, Dobrazanski MJ, Kantor JA, et al. Induction of murine T lymphocyte responses to epitopes of point mutated ras P21. American Association Of Cancer Research, Annual Meeting, Orlando, Florida, 1993.
Abrams SI, Dobrazanski MJ, Kantor JA, et al. Activation of murine CD+ T lumphocyte responses to epitopes of point mutated ras p21. Eur J Immunol 1995; 25: 2588–2597.
Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. JNatl Cancer bast 1993; 85: 1294–1302.
Skipper J, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epotopes in the ras protein. J Exp Med 1993; 177: 1493–1498.
Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly-Asp), are cytotoxic towards a carcinoma cell linerbouring the same mutation. Cancer Immunol Immunother 1995; 40: 165–172.
Fossum B, Breivik J, Meling GI, et al. A K-ras 13 Gly-*Asp mutation is recognized by HLA-DQ7 restricted T cell in a patient with colorectal cancer: Modifying effect of DQ7 restricted T cell in a patient with colorectal cancer: Modifying effect of DQ7 on established cancer harboring this mutation. Int J Cancer 1994; 58: 506–511.
Fossum B, Gedde-Dahl T III, Breivik J, Eriksen JA, Spurkland A, Thorsby E, et al. p-21 ras-peptidespecific T-cell responses in a patient with colorectal cancer: CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation. Int J Cancer 1994; 56: 40–45.
Gedde-Dahl TI, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize pepides derived from mutated p21 ras. lot Immunol 1992; 4: 1331–1337.
Gedde-Dahl TI, Fossum B, Eriksen JA, Thorsby E, Guadernack G. T cell clones specific for p-21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 1993; 23: 754–760.
Gedde-Dahl T III, Spurkland A, Fossum B, Wittinghofer A, Thorsby E, Gaudernack G. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J Immunol 1994; 24: 410–414.
Smith MC, Pendleton CD, Maher VE, Kelley MJ, Carbone DP, Berzofsky JA. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. Int Immunol 1997; 9: 1085–1093.
Van Elsas A, Nijman HW, Van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 Ras peptide presented by HLA-A-201. Int J Cancer 1995; 61: 389–396.
Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, et al. Generation of Stable CD4+ and CD8+ T cell lines from patints immunized with mutated Ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997; 182: 137–151.
Wojtowicz M, Hamilton M, Benrnstein S, et al. Clinical Trial of Mutant Ras Peptide Vaccination Along with IL-2 or GM-CSF. Proc Am Soc Clin Oncol 2000: 1818.
Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Valdependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997; 72: 784–790.
Tsang KY, Nieroda CA, DeFilippi R, et al. Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 1994; 3: 183–193.
Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92: 441–450.
Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19: 1848–1854.
Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453–456.
El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825.
Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935–944.
Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIPI by a p53-independent pathway. Cancer Res 1994; 54: 3391–3395.
Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318–1327.
Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–708.
Fearon ER, Vogelstein B. A Genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.
Chiba I, Takahashi T, Nau MM, et al. Mutation in the p53 gene are frequent in primary resected non small lung cancer. Oncogene 1990: 1603–1610.
Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 53: 3103–3108.
Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor supressor gene in human cancers: Confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 1996; 56: 2130–2136.
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878.
Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1: 101–110.
Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994; 91: 3171–3175.
Ciernik IF, Berzofsky J, Carbone DP. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma 1995; 14: 139–142.
Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995; 92: 2219–2223.
Gabrilovich DI, Cunningham HT, Carbone DP. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 1996; 19: 414–418.
Lacabanne V, Viguier M, Guillet JG, Choppin J. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 1996; 26: 2635–2639.
Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine Ai p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93: 4781–4786.
Zeh H Jr, Leder GH, Lotze MT, et al. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 1994; 39: 79–86.
Stuber G, Leder GH, Storkus WT, et al. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994; 24: 765–768.
Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23: 2072–2077.
Nijman HW, Houbiers JG, van der Burg SH, et al. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 1993; 14: 121–126.
Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 1995; 25: 1638–1642.
Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328–333.
McCarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JD. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58: 2601–2605.
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830.
Kloetzer W, Kurzrock R, Smith L, et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985; 140: 230–238.
Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990–998.
Chen W, Peace DJ, Rovira DK, You SG, Cheever MA. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 1992; 89: 1468–1472.
Chen W, Qin H, Reese VA, Cheever MA. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother 1998; 21: 257–268.
Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88: 3522–3527.
ten Bosch GJ, Kessler JH, Joosten AM, et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999; 94: 1038–1045.
Greco G, Fruci D, Accapezzato D, et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693–699.
Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684.
Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587–3592.
Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781–1787.
Goletz TJ, Zhan S, Pendleton CD, Heiman LJ, Berzofsky J. Cytotoxic T Cell responses against the EWS/FLI-1 Ewing sarcoma fusion protein and the PAX/FKHR alveolar rhabdomyosarcoma fusion protein. Proc Am Assoc Cancer Res 1996: 3243.
Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087–4091.
Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol 1989; 16: 148–155.
Looi LM, Cheah PL. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol 1998; 20: 19–23.
Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62: 245–252.
Lachman LB, Rao XM, Kremer RH, Ozpolat B, Kiriakova G, Price JE. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 2001; 8: 259–268.
Chen Y, Emtage P, Zhu Q, et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 2001; 8: 316–323.
Foy TM, Bannink J, Sutherland RA, et al. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 2001; 19: 2598–2606.
Wei WZ, Shi WP, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81: 748–754.
Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60: 3782–3789.
Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cell specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1994; 54: 1071–1076.
Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominent peptide of HER-2 neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J Exp Med 1995; 181: 2109–2117.
Ikuta Y, Okugawa T, Furugen R, et al. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Mt J Cancer 2000; 87: 553–558.
Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Res 1999; 19: 2471–2475.
Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER- 2/neu+ tumors. Cancer Res 1998; 58: 4902–4908.
Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine responses to class II HER2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998; 4: 2015–2024.
Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78: 202–208.
Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289–1297.
Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477–484.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–1136.
Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934–937.
Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical infra-epithelial neoplasia and cervical cancer. Int J Cancer 1999; 82: 203–207.
Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997; 89: 1285–1293.
Chen L, Thomas EK, Hu SL, et al. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110–114.
Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996; 56: 3967–3974.
Feltkamp MG, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242–2249.
Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57: 2943–2950.
Kast WM, Brant RM, Drijfhout JW, et al. Human Leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomaviris the 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. Immunotherapy 1993; 14: 115–120.
Kast WM, Brandt RM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904–3912.
Ressing ME, Sette A, Brandt RM, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA- A*0201-binding peptides. J Immunol 1995; 154: 5934–5943.
Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for syngeneic tumor expressing the E6 protein of human papillomavirus type 16. J Immunol 1992; 148: 2617–2621.
Alexander M, Salgaller ML, Celis E, et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996; 175: 1586–1593.
Wojtowicz M, Hamilton JM, Khong H, et al. Vaccination of cervical cancer patients with papilloma virus type 16 E6 and E7 Peptides. American Society of Clinical Oncology, Atlanta, GA, 1999.
Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive [in process citation]. Clin Cancer Res 2000; 6: 3406–3416.
Kadish AS, Ho G, Wang Y, et al. Antigen-specific cell mediated immunity in phase I dose-escalation trial of single doses of Hspe7 in healthy volunteers. Thirty-Sixth Annual Meeting of the American Society for Clinical Oncology, New Orleans, LA, 2000. Vol. 19.
Palefsky JM, Goldstone LS, Boux LJ, Neefe JR. Pathological response to treatment with HspE7 in anal dysplasia of multiple HPV types. Cancer Vaccine 2000, New York, NY, 2000.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc. Totowa, NJ
About this chapter
Cite this chapter
Khleif, S.N., Lucci, J.A. (2003). Oncogenes as Targets for Cancer Vaccines. In: Rak, J. (eds) Oncogene-Directed Therapies. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-313-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-59259-313-2_21
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9738-0
Online ISBN: 978-1-59259-313-2
eBook Packages: Springer Book Archive